

Nobuyuki Yamamoto

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5909152/publications.pdf>

Version: 2024-02-01

198
papers

12,918
citations

66343

42
h-index

24982

109
g-index

206
all docs

206
docs citations

206
times ranked

10871
citing authors

#	ARTICLE	IF	CITATIONS
1	Phase III Clinical Trial for the Combination of Erlotinib Plus Ramucirumab Compared With Osimertinib in Previously Untreated Advanced or Recurrent Non-Small Cell Lung Cancer Positive for the L858R Mutation of EGFR: REVOL858R (WJOG14420L). <i>Clinical Lung Cancer</i> , 2022, 23, e257-e263.	2.6	10
2	Predictive value of EGFR mutation in non-small cell lung cancer patients treated with platinum doublet postoperative chemotherapy. <i>Cancer Science</i> , 2022, 113, 287-296.	3.9	10
3	Real-world data on NGS using the OncoPrint DxTT for detecting genetic alterations in non-small cell lung cancer: WJOG13019L. <i>Cancer Science</i> , 2022, 113, 221-228.	3.9	31
4	Pre-treatment serum protein levels predict survival of non-small cell lung cancer patients without durable clinical benefit by PD-1/L1 inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2109-2116.	4.2	5
5	Phase II study of atezolizumab with bevacizumab for non-squamous non-small cell lung cancer with high PD-L1 expression (@Be Study). , 2022, 10, e004025.		22
6	A Real-World Study on the Effectiveness and Safety of Pembrolizumab Plus Chemotherapy for Nonsquamous NSCLC. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100265.	1.1	15
7	A Randomized Phase II Study Comparing Nivolumab with Carboplatin+Pemetrexed for EGFR-Mutated NSCLC with Resistance to EGFR Tyrosine Kinase Inhibitors (WJOG8515L). <i>Clinical Cancer Research</i> , 2022, 28, 893-902.	7.0	35
8	Efficacy of platinum agents for stage III non-small-cell lung cancer following platinum-based chemoradiotherapy: a retrospective study. <i>BMC Cancer</i> , 2022, 22, 342.	2.6	2
9	Creation of an Integrated Clinical Trial Database and Data Sharing for Conducting New Research by the Japan Lung Cancer Society. <i>JTO Clinical and Research Reports</i> , 2022, 3, 100317.	1.1	1
10	Nintedanib plus chemotherapy for nonsmall cell lung cancer with idiopathic pulmonary fibrosis: a randomised phase 3 trial. <i>European Respiratory Journal</i> , 2022, 60, 2200380.	6.7	34
11	The real-world safety of atezolizumab as second-line or later treatment in Japanese patients with non-small-cell lung cancer: a post-marketing surveillance study. <i>Japanese Journal of Clinical Oncology</i> , 2022, , .	1.3	3
12	Histologic transformation of epidermal growth factor receptor-mutated lung cancer. <i>European Journal of Cancer</i> , 2022, 166, 41-50.	2.8	10
13	High-purity Isolation for Genotyping Rare Cancer Cells from Blood Using a Microfluidic Chip Cell Sorter. <i>Anticancer Research</i> , 2022, 42, 407-417.	1.1	1
14	Alternating Therapy with Osimertinib and Afatinib for Treatment-Naive Patients with EGFR-Mutated Advanced Non-Small Cell Lung Cancer: A Single-Group, Open-Label Phase 2 Trial (WJOG10818L). <i>Lung Cancer</i> , 2022, 168, 38-45.	2.0	5
15	Real-world outcomes of pembrolizumab monotherapy in non-small cell lung cancer in Japan: A post-marketing surveillance. <i>Cancer Science</i> , 2022, 113, 3110-3119.	3.9	5
16	Impact of underrepresented populations on clinical outcomes of chemo-immunotherapy for extensive-stage small cell lung cancer: Real-world prospective cohort study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 8567-8567.	1.6	1
17	Brigatinib in Japanese patients (pts) with ALK+ NSCLC: Final results from the phase 2 J-ALTA trial.. <i>Journal of Clinical Oncology</i> , 2022, 40, 9075-9075.	1.6	0
18	The significance of micro-EGFR T790M mutation on EGFR-TKI efficacy in patients with NSCLC: The WJOG13119L study.. <i>Journal of Clinical Oncology</i> , 2022, 40, e21177-e21177.	1.6	1

#	ARTICLE	IF	CITATIONS
19	Nivolumab Retreatment in Non-Small Cell Lung Cancer Patients Who Responded to Prior Immune Checkpoint Inhibitors and Had ICI-Free Intervals (WJOG9616L). <i>Clinical Cancer Research</i> , 2022, 28, 3207-3213.	7.0	7
20	Brigatinib in Japanese Patients With ALK-Positive NSCLC Previously Treated With Alectinib and Other Tyrosine Kinase Inhibitors: Outcomes of the Phase 2 J-ALTA Trial. <i>Journal of Thoracic Oncology</i> , 2021, 16, 452-463.	1.1	51
21	CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 tumor proportion score ≥ 50 . <i>Cancer Science</i> , 2021, 112, 72-80.	3.9	9
22	Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR). <i>Cancer Science</i> , 2021, 112, 388-396.	3.9	16
23	Predicting osimertinib treatment outcomes through EGFR mutant fraction monitoring in the circulating tumor DNA of EGFR T790M-positive patients with non-small cell lung cancer (WJOG8815L). <i>Molecular Oncology</i> , 2021, 15, 126-137.	4.6	12
24	A phase II study of cisplatin plus vinorelbine combined with atezolizumab as adjuvant therapy for completely resected non-small-cell lung cancer with EGFR mutation (West Japan Oncology Group) Tj ETQq0 0 0 rgBLZ Overlook 10 Tf 50		
25	Durvalumab for patients with unresectable stage III non-small cell lung cancer and grade 1 radiation pneumonitis following concurrent chemoradiotherapy: a multicenter prospective cohort study. <i>Investigational New Drugs</i> , 2021, 39, 853-859.	2.6	4
26	Efficacy and Safety of S-1 Compared With Docetaxel in Elderly Patients With Advanced NSCLC Previously Treated With Platinum-Based Chemotherapy: A Subgroup Analysis of the EAST-LC Trial. <i>JTO Clinical and Research Reports</i> , 2021, 2, 100142.	1.1	1
27	Mutational landscape of multiple primary lung cancers and its correlation with non-intrinsic risk factors. <i>Scientific Reports</i> , 2021, 11, 5680.	3.3	11
28	Sequential therapy of crizotinib followed by alectinib for non-small cell lung cancer harbouring anaplastic lymphoma kinase rearrangement (WJOG9516L): A multicenter retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 145, 183-193.	2.8	15
29	Efficacy of Osimertinib Plus Bevacizumab vs Osimertinib in Patients With EGFR T790M-Mutated Non-Small Cell Lung Cancer Previously Treated With Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor. <i>JAMA Oncology</i> , 2021, 7, 386.	7.1	108
30	Bloodborne Cytokines for Predicting Clinical Benefits and Immune-Related Adverse Events in Advanced Non-Small Cell Lung Cancer Treated With Anti-Programmed Cell Death 1 Inhibitors. <i>Clinical Lung Cancer</i> , 2021, 22, e833-e841.	2.6	3
31	Phase II Study of Neoadjuvant Concurrent Chemo-immuno-radiation Therapy Followed by Surgery and Adjuvant Immunotherapy for Resectable Stage IIIA-B (Discrete N2) Non-small-cell Lung Cancer: SQUAT trial (WJOG 12119L). <i>Clinical Lung Cancer</i> , 2021, 22, 596-600.	2.6	14
32	Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naïve expansion cohort.. <i>Journal of Clinical Oncology</i> , 2021, 39, 9042-9042.	1.6	3
33	Tumor expression of cGAS, not STING, negatively impacts on the efficacy of PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 TPS ≥ 50 .. <i>Journal of Clinical Oncology</i> , 2021, 39, e21048-e21048.	1.6	0
34	Longitudinal Evaluation of PD-L1 Expression on Circulating Tumor Cells in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. <i>Cancers</i> , 2021, 13, 2290.	3.7	17
35	A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).. <i>Journal of Clinical Oncology</i> , 2021, 39, 9037-9037.	1.6	5
36	Pembrolizumab plus chemotherapy-induced pneumonitis in chemo-naïve patients with non-squamous non-small cell lung cancer: A multicentre, retrospective cohort study. <i>European Journal of Cancer</i> , 2021, 150, 63-72.	2.8	20

#	ARTICLE	IF	CITATIONS
37	Ramucirumab Plus Erlotinib Versus Placebo Plus Erlotinib in Patients With Untreated Metastatic EGFR-Mutated NSCLC: RELAY Japanese Subset. JTO Clinical and Research Reports, 2021, 2, 100171.	1.1	5
38	EGFR tyrosine kinase inhibitors for EGFR mutation-positive non-small-cell lung cancer: outcomes in Asian populations. Future Oncology, 2021, 17, 2395-2408.	2.4	17
39	RELAY Subgroup Analyses by EGFR Ex19del and Ex21L858R Mutations for Ramucirumab Plus Erlotinib in Metastatic Non-Small Cell Lung Cancer. Clinical Cancer Research, 2021, 27, 5258-5271.	7.0	23
40	Abstract 2976: Establishment of organoids derived from patients with advanced thoracic malignancies. , 2021, , .		0
41	Tumor microenvironment disparity in multiple primary lung cancers: Impact of non-intrinsic factors, histological subtypes, and genetic aberrations. Translational Oncology, 2021, 14, 101102.	3.7	8
42	Pembrolizumab Plus Amrubicin in Patients With Relapsed SCLC: Multi-Institutional, Single-Arm Phase 2 Study. JTO Clinical and Research Reports, 2021, 2, 100184.	1.1	8
43	A Phase II Study to Assess the Efficacy of Osimertinib in Patients With EGFR Mutation-positive NSCLC Who Developed Isolated CNS Progression (T790M-negative or Unknown) During First- or Second-generation EGFR-TKI or Systemic Disease Progression (T790M-negative) After Treatment With First- or Second-generation EGFR-TKI and Platinum-based Chemotherapy (WJOG12819L). Clinical Lung Cancer, 2021, 22, 276-289.	2.6	6
44	A Phase II Study of Osimertinib for Radiotherapy-Naive Central Nervous System Metastasis From NSCLC: Results for the T790M Cohort of the OCEAN Study (LOGIK1603/WJOG9116L). Journal of Thoracic Oncology, 2021, 16, 2121-2132.	1.1	36
45	Phase 3 Trial Comparing Nanoparticle Albumin-Bound Paclitaxel With Docetaxel for Previously Treated Advanced NSCLC. Journal of Thoracic Oncology, 2021, 16, 1523-1532.	1.1	57
46	First-line pembrolizumab vs chemotherapy in metastatic non-small-cell lung cancer: KEYNOTE-024 Japan subset*. Cancer Science, 2021, 112, 5000-5010.	3.9	6
47	Real-world safety of nivolumab in patients with non-small-cell lung cancer in Japan: Postmarketing surveillance. Cancer Science, 2021, 112, 4692-4701.	3.9	14
48	Gefitinib With Concurrent Thoracic Radiotherapy in Unresectable Locally Advanced NSCLC With EGFR Mutation; West Japan Oncology Group 6911L. Journal of Thoracic Oncology, 2021, 16, 1745-1752.	1.1	19
49	Phase Ib Study of Osimertinib Plus Ramucirumab in Japanese Lung Cancer Patients With EGFR Mutation. Anticancer Research, 2021, 41, 911-917.	1.1	4
50	Phase II study of multidisciplinary therapy combined with pembrolizumab for patients with synchronous oligometastatic non-small cell lung cancer TRAP OLIGO study (WJOG11118L). BMC Cancer, 2021, 21, 1121.	2.6	3
51	Rationale and Design for a Multicenter, Phase II Study of Durvalumab Plus Concurrent Radiation Therapy in Locally Advanced Non-Small Cell Lung Cancer: The DOLPHIN Study (WJOG11619L). Cancer Management and Research, 2021, Volume 13, 9167-9173.	1.9	5
52	Predictive impact of low-frequency pretreatment T790M mutation in patients with EGFR-mutated non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors. Lung Cancer, 2020, 139, 80-88.	2.0	9
53	Survival Analysis for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status Treated with Alectinib: Updated Results of Lung Oncology Group in Kyushu 1401. Oncologist, 2020, 25, 306-e618.	3.7	12
54	Therapies after first-line afatinib in patients with EGFR ⁺ NSCLC in Japan: retrospective analysis of LUX-Lung 3. Future Oncology, 2020, 16, 49-60.	2.4	4

#	ARTICLE	IF	CITATIONS
55	Observational Study of Sequential Afatinib and Osimertinib in EGFR Mutation-Positive NSCLC: Patients Treated with a 40-mg Starting Dose of Afatinib. <i>Advances in Therapy</i> , 2020, 37, 759-769.	2.9	8
56	Immune-Related Adverse Events by Immune Checkpoint Inhibitors Significantly Predict Durable Efficacy Even in Responders with Advanced Non-Small Cell Lung Cancer. <i>Oncologist</i> , 2020, 25, e679-e683.	3.7	54
57	Association of immune-related pneumonitis with the presence of preexisting interstitial lung disease in patients with non-small lung cancer receiving anti-programmed cell death 1 antibody. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 15-22.	4.2	54
58	Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2020, 139, 195-199.	2.0	100
59	Randomized Phase III Study of Continuation Maintenance Bevacizumab With or Without Pemetrexed in Advanced Nonsquamous Non-small-Cell Lung Cancer: COMPASS (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2020, 38, 793-803.	1.6	28
60	Prospective, multicentre, single-arm phase II trial of pembrolizumab combined with carboplatin and pemetrexed in elderly patients with advanced, non-squamous non-small cell lung cancer. <i>BMJ Open</i> , 2020, 10, e037746.	1.9	1
61	A phase II study of Osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer: treatment rationale and protocol design of the OCEAN study (LOGIK 1603/WJOG 9116L). <i>BMC Cancer</i> , 2020, 20, 370.	2.6	8
62	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small cell lung cancer: a phase II clinical trial. <i>Investigational New Drugs</i> , 2020, 38, 1854-1861.	2.6	18
63	A randomized phase 3 study of maintenance therapy with Sâ€ plus best supportive care versus best supportive care after induction therapy with carboplatin plus Sâ€ for advanced or relapsed squamous cell carcinoma of the lung (WJOG7512L). <i>Cancer</i> , 2020, 126, 3648-3656.	4.1	2
64	Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-small-Cell Lung Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 2187-2196.	1.6	78
65	Treatment Rationale and Design for APPLE (WJOG11218L): A Multicenter, Open-Label, Randomized Phase 3 Study of Atezolizumab and Platinum/Pemetrexed With or Without Bevacizumab for Patients With Advanced Nonsquamous Non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2020, 21, 472-476.	2.6	12
66	Treatment Sequencing in Patients with Anaplastic Lymphoma Kinase-Positive Non-Small Cell Lung Cancer in Japan: A Real-World Observational Study. <i>Advances in Therapy</i> , 2020, 37, 3311-3323.	2.9	13
67	Survival and prognostic factors in elderly patients receiving second-line chemotherapy for relapsed small-cell lung cancer: Results from the Japanese Joint Committee of Lung Cancer Registry. <i>Lung Cancer</i> , 2020, 146, 160-164.	2.0	6
68	Comparison of Carboplatin Plus Pemetrexed Followed by Maintenance Pemetrexed With Docetaxel Monotherapy in Elderly Patients With Advanced Nonsquamous Non-small Cell Lung Cancer. <i>JAMA Oncology</i> , 2020, 6, e196828.	7.1	48
69	Predictive value of serum VEGF levels for elderly patients or for patients with poor performance status receiving anti-PD-1 antibody therapy for advanced non-small-cell lung cancer. <i>Cancer Immunology, Immunotherapy</i> , 2020, 69, 1229-1236.	4.2	18
70	Differential significance of molecular subtypes which were classified into EGFR exon 19 deletion on the first line afatinib monotherapy. <i>BMC Cancer</i> , 2020, 20, 103.	2.6	14
71	Plasma screening for the T790M mutation of <i>EGFR</i> and phase 2 study of osimertinib efficacy in plasma T790Mâ€positive non-small cell lung cancer: West Japan Oncology Group 8815L/LPS study. <i>Cancer</i> , 2020, 126, 1940-1948.	4.1	18
72	Propensity scoreâ€weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L). , 2020, 8, e000350.		42

#	ARTICLE	IF	CITATIONS
73	A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2020, 38, 1588-1597.	2.6	12
74	Detection of AXL expression in circulating tumor cells of lung cancer patients using an automated microcavity array system. <i>Cancer Medicine</i> , 2020, 9, 2122-2133.	2.8	14
75	RELAY study of erlotinib (ERL) + ramucirumab (RAM) or placebo (PL) in EGFR-mutated metastatic non-small cell lung cancer (NSCLC): Biomarker analysis using circulating tumor DNA (ctDNA) in Japanese patients (pts).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9527-9527.	1.6	1
76	Osimertinib for patients with poor performance status and EGFR T790M mutation-positive advanced non-small-cell lung cancer (NSCLC): A phase II clinical trial.. <i>Journal of Clinical Oncology</i> , 2020, 38, e21704-e21704.	1.6	0
77	A phase II study of osimertinib for patients with radiotherapy-naïve CNS metastasis of non-small cell lung cancer harboring EGFR mutations: The OCEAN study (LOGIK 1603/WJOG 9116L).. <i>Journal of Clinical Oncology</i> , 2020, 38, 9597-9597.	1.6	1
78	Brigatinib in Japanese ALK positive NSCLC patients previously treated with ALK tyrosine kinase inhibitors: J-ALTA.. <i>Journal of Clinical Oncology</i> , 2020, 38, 9537-9537.	1.6	1
79	Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. <i>Supportive Care in Cancer</i> , 2019, 27, 1139-1147.	2.2	21
80	Summary of the Japanese Respiratory Society statement for the treatment of lung cancer with comorbid interstitial pneumonia. <i>Respiratory Investigation</i> , 2019, 57, 512-533.	1.8	36
81	Ramucirumab plus erlotinib in patients with untreated, EGFR-mutated, advanced non-small-cell lung cancer (RELAY): a randomised, double-blind, placebo-controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2019, 20, 1655-1669.	10.7	418
82	Phase II study of nab-paclitaxel+carboplatin for patients with non-small cell lung cancer and interstitial lung disease. <i>Cancer Science</i> , 2019, 110, 3738-3745.	3.9	49
83	Impact of tumor microenvironment on the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in patients with EGFR mutant non-small cell lung cancer. <i>Cancer Science</i> , 2019, 110, 3244-3254.	3.9	32
84	Simple standard equation for daily step count in Japanese patients with chronic obstructive pulmonary disease. <i>International Journal of COPD</i> , 2019, Volume 14, 1967-1977.	2.3	8
85	The Japanese Lung Cancer Society Guideline for non-small cell lung cancer, stage IV. <i>International Journal of Clinical Oncology</i> , 2019, 24, 731-770.	2.2	100
86	Heterogeneous Expression of Programmed Death Receptor-ligand 1 on Circulating Tumor Cells in Patients With Lung Cancer. <i>Clinical Lung Cancer</i> , 2019, 20, 270-277.e1.	2.6	39
87	Tumor expression and usefulness as a biomarker of programmed death ligand 1 in advanced non-small cell lung cancer patients with preexisting interstitial lung disease. <i>Medical Oncology</i> , 2019, 36, 49.	2.5	16
88	Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small cell lung cancer in Japan. <i>Cancer Science</i> , 2019, 110, 1401-1407.	3.9	22
89	Phase I/II Study of Osimertinib With Bevacizumab in EGFR-mutated, T790M-positive Patients With Progressed EGFR-TKIs: West Japan Oncology Group 8715L (WJOG8715L). <i>Clinical Lung Cancer</i> , 2019, 20, e492-e494.	2.6	8
90	Carboplatin Plus Nab-paclitaxel in Performance Status 2 Patients With Advanced Non-small-cell Lung Cancer. <i>Anticancer Research</i> , 2019, 39, 1463-1468.	1.1	5

#	ARTICLE	IF	CITATIONS
91	Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC. <i>International Journal of Clinical Oncology</i> , 2019, 24, 485-493.	2.2	4
92	Predictive value of serum protein levels in patients with advanced non-small cell lung cancer treated with nivolumab. <i>Lung Cancer</i> , 2019, 132, 107-113.	2.0	40
93	Real-world treatment of over 1600 Japanese patients with EGFR mutation-positive non-small cell lung cancer with daily afatinib. <i>International Journal of Clinical Oncology</i> , 2019, 24, 917-926.	2.2	19
94	Sequencing of therapy following first-line afatinib in patients with EGFR mutation-positive non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 132, 126-131.	2.0	26
95	Clinical significance of monitoring EGFR mutation in plasma using multiplexed digital PCR in EGFR mutated patients treated with afatinib (West Japan Oncology Group 8114LTR study). <i>Lung Cancer</i> , 2019, 131, 128-133.	2.0	18
96	Furosemide versus mannitol in Japanese patients with thoracic malignancy who received cisplatin-based chemotherapy using short hydration: study protocol for a randomised controlled trial. <i>BMJ Open</i> , 2019, 9, e029057.	1.9	2
97	The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1/PD-L1 antibodies in non-small cell lung cancer. <i>Lung Cancer</i> , 2019, 128, 113-119.	2.0	11
98	A Phase II Study of Nivolumab in Patients With Advanced Non-small-cell Lung Cancer who Responded to Prior PD-1/L1 Inhibitors: West Japan Oncology Group 9616L (WJOG9616L). <i>Clinical Lung Cancer</i> , 2019, 20, 139-141.	2.6	5
99	Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan. <i>Lung Cancer</i> , 2019, 129, 55-62.	2.0	29
100	A Phase II Study of Gefitinib With Concurrent Thoracic Radiotherapy in Patients With Unresectable, Stage III Non-small-cell Lung Cancer Harboring EGFR Mutations (WJOG6911L). <i>Clinical Lung Cancer</i> , 2019, 20, e25-e27.	2.6	21
101	Randomized phase III study of pemetrexed/cisplatin (Pem/Cis) versus vinorelbine /cisplatin (Vnr/Cis) for completely resected stage II-IIIa non-squamous non-small-cell lung cancer (Ns-NSCLC): The JIPANG study. <i>Journal of Clinical Oncology</i> , 2019, 37, 8501-8501.	1.6	11
102	A randomized phase III study of continuous maintenance bevacizumab with or without pemetrexed after induction therapy with carboplatin (Car), pemetrexed (Pem), and bevacizumab (Bev) for advanced non-squamous non-small cell lung cancer (nSQ-NSCLC) without sensitizing EGFR mutations: The COMPASS study (WJOG5610L). <i>Journal of Clinical Oncology</i> , 2019, 37, 9003-9003.	1.6	3
103	Randomized phase III study comparing carboplatin plus pemetrexed followed by pemetrexed versus docetaxel in elderly patients with advanced non-squamous non-small-cell lung cancer (JCOG1210/WJOG7813L). <i>Journal of Clinical Oncology</i> , 2019, 37, 9031-9031.	1.6	8
104	Final PFS analysis and safety data from the phase III J-ALEX study of alectinib (ALC) vs. crizotinib (CRZ) in ALK-inhibitor naïve ALK-positive non-small cell lung cancer (ALK+ NSCLC). <i>Journal of Clinical Oncology</i> , 2019, 37, 9092-9092.	1.6	14
105	A multicenter, open label, randomized phase III study of atezolizumab with platinum-pemetrexed and with or without bevacizumab for patients with advanced nonsquamous non-small cell lung cancer (WJOG11218L APPLE Study). <i>Journal of Clinical Oncology</i> , 2019, 37, TPS9125-TPS9125.	1.6	3
106	The impact of sequential therapy of crizotinib followed by alectinib: Real-world data analysis of 840 ALK-inhibitor naïve patients with NSCLC harboring ALK-rearrangement (WJOG9516L). <i>Journal of Clinical Oncology</i> , 2019, 37, 9038-9038.	1.6	0
107	Randomized phase 3 study of maintenance therapy with S-1 plus best supportive care (BSC) versus BSC alone after induction therapy with carboplatin plus S-1 for advanced or relapsed squamous cell lung carcinoma (WJOG7512L). <i>Journal of Clinical Oncology</i> , 2019, 37, e20531-e20531.	1.6	0
108	<i>Internal Medicine</i> , 2019, 108, 1772-1776.	0.0	0

#	ARTICLE	IF	CITATIONS
109	Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort. <i>Lung Cancer</i> , 2018, 117, 14-19.	2.0	63
110	Analysis of central nervous system efficacy in the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer. <i>Lung Cancer</i> , 2018, 121, 37-40.	2.0	62
111	Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials. <i>Clinical Lung Cancer</i> , 2018, 19, e465-e479.	2.6	56
112	Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-Cell Lung Cancer With Idiopathic Pulmonary Fibrosis. <i>Clinical Lung Cancer</i> , 2018, 19, e5-e9.	2.6	44
113	Randomized Phase III Study of Cisplatin With Pemetrexed and Cisplatin With Vinorelbine for Completely Resected Nonsquamous Non-Small-Cell Lung Cancer: The JIPANG Study Protocol. <i>Clinical Lung Cancer</i> , 2018, 19, e1-e3.	2.6	16
114	Erlotinib Plus Bevacizumab Phase II Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. <i>Drug Safety</i> , 2018, 41, 229-237.	3.2	48
115	Does EGFR Mutation Type Influence Patient-Reported Outcomes in Patients with Advanced EGFR Mutation-Positive Non-Small-Cell Lung Cancer? Analysis of Two Large, Phase III Studies Comparing Afatinib with Chemotherapy (LUX-Lung 3 and LUX-Lung 6). <i>Patient</i> , 2018, 11, 131-141.	2.7	20
116	Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. <i>Lung Cancer</i> , 2018, 115, 71-74.	2.0	313
117	Economic analysis of palonosetron versus granisetron in the standard triplet regimen for preventing chemotherapy-induced nausea and vomiting in patients receiving highly emetogenic chemotherapy in Japan (TRIPLE phase III trial). <i>Journal of Pharmaceutical Health Care and Sciences</i> , 2018, 4, 31.	1.0	8
118	Induction Chemoradiotherapy (50 Gy), Followed by Resection, for Stage IIIA-N2 Non-Small Cell Lung Cancer. <i>Annals of Thoracic Surgery</i> , 2018, 106, 1018-1024.	1.3	8
119	Osimertinib With Ramucirumab in EGFR-mutated, T790M-positive Patients With Progression During EGFR-TKI Therapy: Phase Ib Study. <i>Clinical Lung Cancer</i> , 2018, 19, e871-e874.	2.6	10
120	Real-World EGFR T790M Testing in Advanced Non-Small-Cell Lung Cancer: A Prospective Observational Study in Japan. <i>Oncology and Therapy</i> , 2018, 6, 203-215.	2.6	47
121	Is prophylactic cranial irradiation (PCI) needed in patients with extensive-stage small cell lung cancer showing complete response to first-line chemotherapy?. <i>Radiotherapy and Oncology</i> , 2018, 127, 344-348.	0.6	11
122	Docetaxel Plus Ramucirumab With Primary Prophylactic Pegylated Granulocyte-Colony Stimulating Factor Support for Elderly Patients With Advanced Non-Small-Cell Lung Cancer: A Multicenter Prospective Single Arm Phase II Trial: DRAGON Study (WJOG9416L). <i>Clinical Lung Cancer</i> , 2018, 19, e865-e869.	2.6	2
123	A Randomized Phase III Study Comparing Carboplatin With Nab-Paclitaxel Versus Docetaxel for Elderly Patients With Squamous-Cell Lung Cancer: Study Protocol. <i>Clinical Lung Cancer</i> , 2018, 19, e711-e715.	2.6	9
124	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutation-positive non-squamous non-small-cell lung cancer (NSCLC): Survival follow-up results of JO25567. <i>Journal of Clinical Oncology</i> , 2018, 36, 9007-9007.	1.6	53
125	Gemcitabine-cisplatin (GC) + necitumumab (N) versus GC as first-line treatment for stage IV squamous cell lung cancer (SqCLC): An open-label randomized multicenter phase Ib-II trial in Japan. <i>Journal of Clinical Oncology</i> , 2018, 36, 9038-9038.	1.6	2
126	Comparison of Clinically Relevant Mutation Profiles Between Preoperative Biopsy and Corresponding Surgically Resected Specimens in Japanese Patients With Non-Small-Cell Lung Cancer by Amplicon-based Massively Parallel Sequencing. <i>Clinical Lung Cancer</i> , 2017, 18, 519-526.e1.	2.6	3

#	ARTICLE	IF	CITATIONS
127	Alectinib for Patients with ALK Rearrangement-Positive Non-Small Cell Lung Cancer and a Poor Performance Status (Lung Oncology Group in Kyushu-1401). <i>Journal of Thoracic Oncology</i> , 2017, 12, 1161-1166.	1.1	42
128	Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial. <i>Lancet</i> , The, 2017, 390, 29-39.	13.7	753
129	Breakthrough chemotherapy-induced nausea and vomiting: report of a nationwide survey by the CINV Study Group of Japan. <i>International Journal of Clinical Oncology</i> , 2017, 22, 405-412.	2.2	23
130	A Randomized Phase II Study Comparing Nivolumab With Carboplatin-Pemetrexed for Patients With EGFR Mutation-Positive Nonsquamous Non-Small-Cell Lung Cancer Who Acquire Resistance to Tyrosine Kinase Inhibitors Not Due to a Secondary T790M Mutation: Rationale and Protocol Design for the WJOG8515L Study. <i>Clinical Lung Cancer</i> , 2017, 18, 719-723.	2.6	13
131	Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 663-671.	10.7	398
132	EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. <i>British Journal of Cancer</i> , 2017, 116, 175-185.	6.4	76
133	PIK3CA mutation as a distinctive genetic feature of non-small cell lung cancer with chronic obstructive pulmonary disease: A comprehensive mutational analysis from a multi-institutional cohort. <i>Lung Cancer</i> , 2017, 112, 96-101.	2.0	17
134	Prophylactic cranial irradiation in small-cell lung cancer - Authors' reply. <i>Lancet Oncology</i> , The, 2017, 18, e369.	10.7	3
135	Sequential Therapy with Crizotinib and Alectinib in ALK -Rearranged Non-Small Cell Lung Cancer - A Multicenter Retrospective Study. <i>Journal of Thoracic Oncology</i> , 2017, 12, 390-396.	1.1	44
136	Treatment Rationale and Design for J-AXEL: A Randomized Phase 3 Study Comparing Nab-Paclitaxel With Docetaxel in Patients With Previously Treated Advanced Non-Small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2017, 18, 100-103.	2.6	9
137	Efficacy of osimertinib in a patient with non-small cell lung cancer harboring epithelial growth factor receptor exon 19 deletion/T790M mutation, with poor performance status. <i>Molecular and Clinical Oncology</i> , 2017, 8, 246-249.	1.0	6
138	Skeletal muscle depletion during chemotherapy has a large impact on physical function in elderly Japanese patients with advanced non-small-cell lung cancer. <i>BMC Cancer</i> , 2017, 17, 571.	2.6	51
139	Unfavorable impact of cancer cachexia on activity of daily living and need for inpatient care in elderly patients with advanced non-small-cell lung cancer in Japan: a prospective longitudinal observational study. <i>BMC Cancer</i> , 2017, 17, 800.	2.6	46
140	Predictive impact of PD-L1-expressing circulating tumor cells in NSCLC patients treated with nivolumab. <i>Journal of Clinical Oncology</i> , 2017, 35, 11541-11541.	1.6	2
141	Updated efficacy and safety of the j-alex study comparing alectinib (ALC) with crizotinib (CRZ) in ALK-inhibitor naïve ALK+ fusion positive non-small cell lung cancer (ALK+ NSCLC). <i>Journal of Clinical Oncology</i> , 2017, 35, 9064-9064.	1.6	14
142	Nivolumab-induced interstitial lung disease (ILD) in Japanese patients with non-small cell lung cancer: A study on risk factors using interim results of post-marketing all-case surveillance. <i>Journal of Clinical Oncology</i> , 2017, 35, 9078-9078.	1.6	10
143	Development of an automated size-based filtration system for isolation of circulating tumor cells in lung cancer patients. <i>PLoS ONE</i> , 2017, 12, e0179744.	2.5	33
144	Predictive impact of complete molecular response in plasma: A phase II, liquid biopsy study in EGFR mutated NSCLC patients treated with afatinib (WJOG 8114LTR). <i>Journal of Clinical Oncology</i> , 2017, 35, 9027-9027.	1.6	0

#	ARTICLE	IF	CITATIONS
145	2. State of the Art of EGFR-TKI and Future Perspectives. The Journal of the Japanese Society of Internal Medicine, 2017, 106, 1096-1100.	0.0	0
146	Differences in physical activity according to mMRC grade in patients with COPD. International Journal of COPD, 2016, Volume 11, 2203-2208.	2.3	31
147	Re-biopsy status among non-small cell lung cancer patients in Japan: A retrospective study. Lung Cancer, 2016, 101, 1-8.	2.0	118
148	Bevacizumab for non-small cell lung cancer: A nested case control study of risk factors for hemoptysis. Cancer Science, 2016, 107, 1837-1842.	3.9	17
149	Applicability of the Japanese equation for estimating glomerular filtration rate in patients with advanced-stage thoracic cancer. Respiratory Investigation, 2016, 54, 479-483.	1.8	0
150	A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy. Lung Cancer, 2016, 99, 186-193.	2.0	88
151	Phase II study of erlotinib plus tivantinib (ARQ 197) in patients with locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer just after progression on EGFR-TKI, gefitinib or erlotinib. ESMO Open, 2016, 1, e000063.	4.5	37
152	Erlotinib for Japanese patients with activating EGFR mutation-positive non-small-cell lung cancer: combined analyses from two Phase II studies. Future Oncology, 2016, 12, 2117-2126.	2.4	13
153	Pseudoprogression of Pulmonary Pleomorphic Carcinoma during Nivolumab Therapy. Journal of Thoracic Oncology, 2016, 11, e117-e119.	1.1	28
154	Characteristics and overall survival of EGFR mutation-positive non-small cell lung cancer treated with EGFR tyrosine kinase inhibitors: a retrospective analysis for 1660 Japanese patients. Japanese Journal of Clinical Oncology, 2016, 46, 462-467.	1.3	54
155	First-Line Afatinib versus Chemotherapy in Patients with Non-Small Cell Lung Cancer and Common Epidermal Growth Factor Receptor Gene Mutations and Brain Metastases. Journal of Thoracic Oncology, 2016, 11, 380-390.	1.1	300
156	Alectinib (ALC) versus crizotinib (CRZ) in ALK-inhibitor naive ALK-positive non-small cell lung cancer (ALK+ NSCLC): Primary results from the J-ALEX study. Journal of Clinical Oncology, 2016, 34, 9008-9008.	1.6	58
157	Patterns of PD-L1 expression on circulating tumor cells in Japanese patients with advanced lung cancer. Journal of Clinical Oncology, 2016, 34, e23036-e23036.	1.6	0
158	Overall survival (OS) of EGFR mutation-positive non-small cell lung cancer (NSCLC) patients: Real-world treatment patterns of 1,660 Japanese patients (pts). Journal of Clinical Oncology, 2016, 34, e20503-e20503.	1.6	0
159	Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6. Lancet Oncology, The, 2015, 16, 830-838.	10.7	786
160	Progression of Irreversible Airflow Limitation in Asthma: Correlation with Severe Exacerbations. Journal of Allergy and Clinical Immunology: in Practice, 2015, 3, 759-764.e1.	3.8	47
161	Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non-small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX-Lung 3. Cancer Science, 2015, 106, 1202-1211.	3.9	99
162	Randomized Phase III Trial Comparing Weekly Docetaxel Plus Cisplatin Versus Docetaxel Monotherapy Every 3 Weeks in Elderly Patients With Advanced Non-Small-Cell Lung Cancer: The Intergroup Trial JCOG0803/WJOG4307L. Journal of Clinical Oncology, 2015, 33, 575-581.	1.6	109

#	ARTICLE	IF	CITATIONS
163	Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. <i>Lancet Oncology</i> , The, 2015, 16, 141-151.	10.7	1,369
164	A review of biomechanics of the shoulder and biomechanical concepts of rotator cuff repair. <i>Asia-Pacific Journal of Sports Medicine, Arthroscopy, Rehabilitation and Technology</i> , 2015, 2, 27-30.	1.0	9
165	Disease flare after gefitinib discontinuation. <i>Respiratory Investigation</i> , 2015, 53, 68-72.	1.8	10
166	Nedaplatin plus docetaxel versus cisplatin plus docetaxel for advanced or relapsed squamous cell carcinoma of the lung (WJOG5208L): a randomised, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 1630-1638.	10.7	75
167	Randomized phase III study of nedaplatin (N) plus docetaxel (D) versus cisplatin (C) plus D for advanced or relapsed squamous cell carcinoma of the lung (SqLC): WJOG5208L.. <i>Journal of Clinical Oncology</i> , 2015, 33, 8004-8004.	1.6	2
168	Influence of dose adjustment on afatinib safety and efficacy in patients (pts) with advanced EGFR mutation-positive (EGFRm+) non-small cell lung cancer (NSCLC).. <i>Journal of Clinical Oncology</i> , 2015, 33, 8073-8073.	1.6	6
169	Final overall survival results of a randomized phase III trial comparing weekly docetaxel plus cisplatin (DP) with 3-weekly docetaxel (D) monotherapy in elderly patients (pts) with advanced non-small-cell lung cancer (NSCLC): intergroup trial JCOG0803/WJOG4307L.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19012-e19012.	1.6	1
170	High-Density Dielectrophoretic Microwell Array for Detection, Capture, and Single-Cell Analysis of Rare Tumor Cells in Peripheral Blood. <i>PLoS ONE</i> , 2015, 10, e0130418.	2.5	43
171	Progression-free survival, post-progression survival, and tumor response as surrogate markers for overall survival in patients with extensive small cell lung cancer. <i>Annals of Thoracic Medicine</i> , 2015, 10, 61-6.	1.8	30
172	Overall response rate as a surrogate of progression-free survival with molecular targeted agents: A meta-analysis of phase III trials in advanced non-small cell lung cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, e19142-e19142.	1.6	0
173	Multiplexed Molecular Profiling of Lung Cancer Using Pleural Effusion. <i>Journal of Thoracic Oncology</i> , 2014, 9, 1048-1052.	1.1	36
174	Current status and future perspectives of cooperative study groups for lung cancer in Japan. <i>Respiratory Investigation</i> , 2014, 52, 339-347.	1.8	3
175	A single-arm confirmatory study of amrubicin therapy in patients with refractory small-cell lung cancer: Japan Clinical Oncology Group Study (JCOG0901). <i>Lung Cancer</i> , 2014, 84, 67-72.	2.0	62
176	Changes in forced expiratory volume in 1 second over time in patients with controlled asthma at baseline. <i>Respiratory Medicine</i> , 2014, 108, 976-982.	2.9	19
177	Molecular profiling of small cell lung cancer in a Japanese cohort. <i>Lung Cancer</i> , 2014, 84, 139-144.	2.0	32
178	TLR3 Activation Augments Matrix Metalloproteinase Production through Reactive Nitrogen Species Generation in Human Lung Fibroblasts. <i>Journal of Immunology</i> , 2014, 192, 4977-4988.	0.8	24
179	Identification of actionable mutations in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2014, 86, 35-40.	2.0	26
180	Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study. <i>Lancet Oncology</i> , The, 2014, 15, 1236-1244.	10.7	678

#	ARTICLE	IF	CITATIONS
181	Ongoing Allergic Rhinitis Impairs Asthma Control by Enhancing the Lower Airway Inflammation. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2014, 2, 172-178.e1.	3.8	40
182	Toxicity and efficacy of chemotherapy for non-small cell lung cancer with cavitory lesions. <i>Respiratory Investigation</i> , 2014, 52, 184-189.	1.8	8
183	Prophylactic cranial irradiation (PCI) has a detrimental effect on the overall survival (OS) of patients (pts) with extensive disease small cell lung cancer (ED-SCLC): Results of a Japanese randomized phase III trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7503-7503.	1.6	29
184	Overall survival (OS) in patients (pts) with advanced non-small cell lung cancer (NSCLC) harboring common (Del19/L858R) epidermal growth factor receptor mutations (EGFR mut): Pooled analysis of two large open-label phase III studies (LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6]) comparing afatinib with chemotherapy (CT).. <i>Journal of Clinical Oncology</i> , 2014, 32, 8004-8004.	1.6	34
185	Erlotinib plus bevacizumab (EB) versus erlotinib alone (E) as first-line treatment for advanced EGFR mutationâ€“positive nonsquamous non-small cell lung cancer (NSCLC): An open-label randomized trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8005-8005.	1.6	10
186	Tivantinib plus erlotinib versus placebo plus erlotinib in Asian patients with previously treated nonsquamous NSCLC with wild-type <i>EGFR</i>. First report of a phase III ATTENTION trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8044-8044.	1.6	9
187	Phase II study of erlotinib plus tivantinib in patients with <i>EGFR</i>-mutationâ€“positive NSCLC who failed in immediately previous EGFR-TKI therapy.. <i>Journal of Clinical Oncology</i> , 2014, 32, 8052-8052.	1.6	5
188	Clinical characteristics and molecular profile in patients with non-small cell lung cancer harboring <i>CRKL</i> amplification.. <i>Journal of Clinical Oncology</i> , 2014, 32, 7567-7567.	1.6	0
189	Multimutational profiling of rebiopsy samples from NSCLC developing acquired resistance to EGFR-TKI in Japanese patients.. <i>Journal of Clinical Oncology</i> , 2014, 32, e19032-e19032.	1.6	0
190	Exploratory analysis of serum and urine biomarkers associated with chemotherapy-induced nausea and vomiting.. <i>Journal of Clinical Oncology</i> , 2014, 32, e20716-e20716.	1.6	0
191	Identification of metabolic signatures associated with erlotinib resistance of non-small cell lung cancer cells. <i>Anticancer Research</i> , 2014, 34, 2779-87.	1.1	18
192	Phase I study of Efatutazone, an oral PPAR ^{Î³} agonist, in patients with metastatic solid tumors. <i>Anticancer Research</i> , 2014, 34, 5133-41.	1.1	15
193	Pemetrexed and carboplatin followed by pemetrexed maintenance therapy in chemo-na ^Ã ve patients with advanced nonsquamous non-small-cell lung cancer. <i>Investigational New Drugs</i> , 2013, 31, 1275-1282.	2.6	38
194	Phase III Study of Afatinib or Cisplatin Plus Pemetrexed in Patients With Metastatic Lung Adenocarcinoma With <i>EGFR</i> Mutations. <i>Journal of Clinical Oncology</i> , 2013, 31, 3327-3334.	1.6	2,854
195	CH5424802 (RO5424802) for patients with ALK-rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1â€“2 study. <i>Lancet Oncology</i> , The, 2013, 14, 590-598.	10.7	555
196	Microcavity Array System for Size-Based Enrichment of Circulating Tumor Cells from the Blood of Patients with Small-Cell Lung Cancer. <i>Analytical Chemistry</i> , 2013, 85, 5692-5698.	6.5	89
197	Size-Based Isolation of Circulating Tumor Cells in Lung Cancer Patients Using a Microcavity Array System. <i>PLoS ONE</i> , 2013, 8, e67466.	2.5	151
198	Phase III Study Comparing Second- and Third-Generation Regimens With Concurrent Thoracic Radiotherapy in Patients With Unresectable Stage III Nonâ€“Small-Cell Lung Cancer: West Japan Thoracic Oncology Group WJTOG0105. <i>Journal of Clinical Oncology</i> , 2010, 28, 3739-3745.	1.6	261